Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Trinity Biotech (TRIB) Convertible Debt (2022 - 2024)

Trinity Biotech's Convertible Debt history spans 3 years, with the latest figure at $15.4 million for Q4 2024.

  • On a quarterly basis, Convertible Debt rose 5.91% to $15.4 million in Q4 2024 year-over-year; TTM through Dec 2024 was $15.4 million, a 5.91% increase, with the full-year FY2024 number at $15.4 million, up 5.91% from a year prior.
  • Convertible Debt hit $15.4 million in Q4 2024 for Trinity Biotech, up from $15.2 million in the prior quarter.
  • Over the last five years, Convertible Debt for TRIB hit a ceiling of $15.4 million in Q4 2024 and a floor of $13.4 million in Q2 2022.
  • Historically, Convertible Debt has averaged $14.4 million across 3 years, with a median of $14.3 million in 2023.
  • Biggest five-year swings in Convertible Debt: increased 5.72% in 2023 and later grew 5.91% in 2024.
  • Tracing TRIB's Convertible Debt over 3 years: stood at $13.7 million in 2022, then rose by 5.79% to $14.5 million in 2023, then rose by 5.91% to $15.4 million in 2024.
  • Business Quant data shows Convertible Debt for TRIB at $15.4 million in Q4 2024, $15.2 million in Q3 2024, and $15.0 million in Q2 2024.